Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 4/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.31 |
| ▸ | FEN1 | P39748 | 2/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | NEK2 | P51955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204525 | 0.80 | FYN (0.41) | FYN | |
| SCHEMBL5203320 | 0.78 | KDM1A (0.33) | KDM1ASCN9AFYNALOX5APFEN1 | |
| SCHEMBL5203600 | 0.77 | SCN9A (0.36) | KDM1ASCN9AFYNCYP17A1PDE4B | |
| SCHEMBL5203313 | 0.77 | SCN9A (0.33) | KDM1ASCN9AFYNCYP17A1PDE4B | |
| Hydrochloric Acid SCHEMBL5208557 | 0.77 | KDM1A (0.33) | KDM1ASCN9AALOX5APFEN1AAK1 | |
| SCHEMBL5206025 | 0.77 | KDM1A (0.42) | KDM1ASCN9AFYNALOX5APFEN1 | |
| Hydrochloric Acid SCHEMBL5204974 | 0.76 | SCN9A (0.33) | KDM1ASCN9AFYNCYP17A1PDE4B | |
| SCHEMBL5207778 | 0.76 | CYP17A1 (0.36) | KDM1ASCN9ACYP17A1PDE4B | |
| SCHEMBL5205885 | 0.73 | HIF1A (0.45) | PDE4B | |
| SCHEMBL5207081 | 0.71 | CYP17A1 (0.39) | SCN9AFYNCYP17A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403251-B1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-6890940-B2 | Bis(2-aryl-5-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1403251-A1 | BIS(2-ARYL-5-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | KOWA CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022886-A1 | Immoglobulin E (IgE) antibody production inhibitor; treating allergic immune diseases such as asthma, dermatitis, inflammatory bowel disease and allergic opthalmopathy | IGLV6-57, IL5, IGSF11 | KDM1A 2363/4885SCN9A 1642/4885FYN 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.